MG
Marc Goodman Leerink Partners Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Biohaven
BHVN
$1.7B
| $16.07 | $50 |
211%
upside
| Outperform | 23 days ago |
|
2
Amylyx Pharmaceuticals
AMLX
$887M
| $9.95 | $10 |
1%
upside
| Outperform | 4 months ago |
|
3
Axsome Therapeutics
AXSM
$6.21B
| $124.41 | $150 |
21%
upside
| Outperform | 6 months ago |
|
|
LENZ
4
LENZ Therapeutics
LENZ
$1.14B
| $39.92 | $32 |
20%
downside
| Outperform | 1 year ago |
|
|
BLTE
5
Belite Bio
BLTE
$2.14B
| $65.14 | $25 |
62%
downside
| Outperform | 2 years ago |
|
6
Denali Therapeutics
DNLI
$2.16B
| $14.79 | $50 |
238%
upside
| Outperform | 2 years ago |
|
|
7
Biohaven
BHVN
$1.7B
| $16.07 | $24 |
49%
upside
| Outperform | 2 years ago |
|
8
Evolus
EOLS
$486M
| $7.51 | $20 |
166%
upside
| Outperform | 2 years ago |
|
|
9
Axsome Therapeutics
AXSM
$6.21B
| $124.41 | $85 |
32%
downside
| Outperform | 2 years ago |
|
10
Neurocrine Biosciences
NBIX
$13.9B
| $140.40 | $115 |
18%
downside
| Market Perform | 2 years ago |
|
11
Biogen
BIIB
$20.5B
| $139.94 | $310 |
122%
upside
| Outperform | 2 years ago |
|
|
12
Amylyx Pharmaceuticals
AMLX
$887M
| $9.95 | $50 |
403%
upside
| Outperform | 3 years ago |
|
|
AVDL
13
Avadel Pharmaceuticals
AVDL
$1.46B
| $14.99 | $12 |
20%
downside
| Outperform | 3 years ago |
|
14
Xenon Pharmaceuticals
XENE
$2.98B
| $38.64 | $46 |
19%
upside
| Outperform | 3 years ago |
|
15
Acadia Pharmaceuticals
ACAD
$4.3B
| $25.50 | $21 |
18%
downside
| Outperform | 3 years ago |
|
16
Jazz Pharmaceuticals
JAZZ
$7.77B
| $128.02 | $210 |
64%
upside
| Outperform | 3 years ago |
|
17
Alkermes
ALKS
$4.77B
| $28.92 | $27 |
7%
downside
| Market Perform | 3 years ago |
|
18
Aldeyra Therapeutics
ALDX
$332M
| $5.53 | $15 |
171%
upside
| Outperform | 3 years ago |
|
19
Ulta Beauty
ULTA
$23.7B
| $529.50 | $270 |
49%
downside
| Buy | 5 years ago |
|